While the United States on Wednesday reached an agreement with Pfizer Inc. for another 100 million doses of the Covid-19 vaccine, cases of allergic reactions would have prompted discussions between vaccine manufacturers and the National Institutes of Health (NIH) to run clinics. studies on very allergic populations. According to a CNN report, the tsar of US President Donald Trump’s Covid-19 vaccine said the frequency of allergic reactions to the Pfizer vaccine was higher than expected.
“This frequency, as it was yesterday (December 22), is higher than what could be expected with other vaccines,” said Dr. Moncef Slaoui, chief scientific adviser for Operation Warp Speed, quoted by the network. American press.
UK regulators have already issued an opinion on the issue, urging people with a history of “significant” allergic reactions not to receive the Pfizer-BioNTech vaccine. The Medicines and Medicines Regulatory Agency (MHRA) has issued precautionary statements to the National Health Service (NHS) after two members of the medical staff had allergic reactions. Dr. June Raine, chief executive of the MHRA, testified before a parliamentary committee where she acknowledged that allergic reactions do not occur in extensive clinical trials.
“We know from very extensive clinical trials that this was not a feature. But if we need to strengthen our advice, now that we have had this experience in vulnerable populations – groups have been selected as a priority – we immediately receive this advice on the ground, ”said Dr. Raine.
The United States began fighting the immunization against coronavirus disease after the Food and Drug Administration (FDA) granted emergency use of Pfizer-BioNTech, followed by Moderna. Under the new Covid-19 Pfizer supplemental dose agreement, the US drug and its German partner BioNTech will deliver at least 70 million doses by June 30, and the remaining doses will be delivered by July 31 at the latest.